Core Viewpoint - The company has received notification from its cornerstone investor, Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., agreeing to extend the lock-up period for its H shares until December 31, 2025, indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1 - The cornerstone investor will not reduce its holdings in any related H shares from the expiration of the original lock-up period [1] - The extension of the lock-up period reflects the cornerstone investor's confidence in the company's research and development capabilities [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]
派格生物医药-B：基石投资者自愿延长禁售期